Simplified Algorithm for Treatment Eligibility
NCT02891135 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1077
Last updated 2021-01-22
Summary
In its 2015 revision of the global guidelines for HIV care and treatment, the World Health Organization called for initiating lifelong antiretroviral treatment (ART) for all patients testing positive for HIV, regardless of CD4 cell count. As countries adopt the new recommendation, known as "treat all," millions of additional patients are becoming eligible for ART worldwide. In sub-Saharan Africa, where most of these patients are located, studies continue to document high losses of treatment-eligible patients from care before they receive their first dose of antiretroviral medications. Among facility-level reasons for these losses are treatment initiation protocols that require multiple clinic visits and long waiting times before a patient who tests positive for HIV is dispensed an initial supply of medications. Simpler, more efficient, accelerated algorithms for ART initiation will be needed if "treat all" is to realize the benefits expected.
Experts have proposed a simplified clinical algorithm to screen patients for eligibility for immediate ART initiation at a patient's first clinic visit, without the use of point-of-care laboratory test technologies. The Simplified Algorithm for Treatment Eligibility (SLATE) uses four screens to assess whether a patient is eligible for same-day treatment initiation: i) symptom report, ii) medical history, iii) brief physical examination; and iv) readiness assessment. SLATE is a pragmatic, individually randomized evaluation to determine the effectiveness of the algorithm in increasing ART initiation among non-pregnant adult patients. Approximately 960 HIV-infected adult patients not yet on ART will be enrolled during a routine clinic visit and randomized to receive the intervention or standard care. Patients in the intervention arm will be administered the SLATE screens; those found eligible under the algorithm will be offered immediate treatment initiation, while those who are not eligible will be referred for standard clinic care. Patients in the standard arm will be referred for ART initiation under standard clinic procedures. All care after the initial visit will be by the clinic under standard of care. If successful, SLATE will offer a standardized approach to collecting and interpreting a minimum set of patient data that will avoid delaying treatment initiation for the majority of patients who are eligible for immediate ART, while deferring initiation in the minority who should not start immediately.
Conditions
Interventions
- OTHER
-
SLATE
Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
Sponsors & Collaborators
-
University of Witwatersrand, South Africa
collaborator OTHER -
Kenya Medical Research Institute
collaborator OTHER -
Boston University
lead OTHER
Principal Investigators
-
Sydney Rosen · Boston University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-06
- Primary Completion
- 2018-04-23
- Completion
- 2020-12-31
Countries
- Kenya
- South Africa
Study Locations
More Related Trials
-
Immediate ART in Subjects With Opportunistic Diseases
NCT03825523 ·Status: COMPLETED ·Phase: NA
-
Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection
NCT02551523 ·Status: UNKNOWN ·Phase: PHASE2
-
Dolutegravir Impact on Residual Replication
NCT02500446 ·Status: COMPLETED ·Phase: PHASE4
-
Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV
NCT04249037 ·Status: TERMINATED ·Phase: PHASE4
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
NCT06374758 ·Status: RECRUITING ·Phase: PHASE4
-
Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
NCT06485154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01533259 ·Status: COMPLETED ·Phase: PHASE3
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
NCT02656511 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
NCT00749580 ·Status: COMPLETED ·Phase: NA
-
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
NCT01295515 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
NCT01900080 ·Status: UNKNOWN ·Phase: NA
-
First in Human Study of TLC-ART 101 (ACTU 2001)
NCT05850728 ·Status: COMPLETED ·Phase: PHASE1
-
Individualized Antiretroviral Therapy
NCT03385473 ·Status: COMPLETED ·Phase: NA
-
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 ·Status: RECRUITING
-
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
NCT00014937 ·Status: COMPLETED ·Phase: NA
-
A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment
NCT00001069 ·Status: TERMINATED
-
Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa
NCT04066036 ·Status: COMPLETED
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
The Intensified Treatment Monitoring Strategy to Prevent Accumulation of Drug Resistance (ITREMA) Trial
NCT03357588 ·Status: COMPLETED ·Phase: NA
-
Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
NCT00743340 ·Status: COMPLETED ·Phase: PHASE2
-
Empiric Treatment for Acute HIV in the ED
NCT03711253 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings
NCT02777229 ·Status: COMPLETED ·Phase: PHASE3
-
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
NCT01245101 ·Status: TERMINATED ·Phase: PHASE4
-
Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis
NCT02750059 ·Status: COMPLETED ·Phase: PHASE2
-
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
NCT05312918 ·Status: UNKNOWN